ERBB2 and triple-negative breast carcinoma: Notable examples include the approval of trastuzumab emtansine (T-DM1) and Sacituzumab govitecan (SG) for HER2-positive and triple-negative breast cancer, respectively.55,77 These milestones illuminate the path forward and reinforce the imperative of continued investment in research and development.